Sapien 3 Performs Well in “Jobs” for Which It Is Not Designed

Using Sapien 3, transcatheter mitral valve replacement to treat failed bioprosthetic valves can be performed with a high degree of technical success.

Buen desempeño de la Sapien 3 en “trabajos” para los que no está diseñada

Failed mitral bioprosthetic valves are truly challenging due to how frequent symptoms are and the high morbidity/mortality associated with a new surgical replacement. Furthermore, there are no catheter options specifically designed to treat this issue.

Sapien 3 was developed as a last resource, but thanks to its good results, it is becoming a consistently good option.

Researchers analyzed prospectively all patients implanted with Sapien 3 to treat a failed mitral prosthesis between 2015 and 2019 included in the Society of Thoracic Surgeons (STS) registry. The primary efficacy endpoint was 1-year mortality, and secondary endpoints included 30-day mortality, New York Heart Association functional class, and valve performance.


Read also: Convalescent Plasma for Severe Pneumonia from COVID-19.


A total of 1529 patients were included; they had undergone a mitral valve-in-valve procedure through transseptal or transapical access in 295 sites. Technical success was achieved in 96.8% of patients and 30-day and 1-year mortality rates were 5.4% and 16.7%, respectively.

Transseptal access was linked to lower 1-year mortality compared with transapical access (15.8% vs. 21.7%; p = 0.03). 

New valve implantation provided immediate and sustained symptomatic relief. Baseline New York Heart Association functional class was III/IV in 87.1% of patients vs. 9.7% after a year.

Conclusion

Transcatheter mitral valve replacement in failed mitral bioprosthetic valves was associated with high technical success, lower 30-day/1-year mortality rates, and significant improvement of heart failure symptoms.

This option should be considered for most patients with failed mitral bioprosthetic valve and favorable anatomy.

Original Title: One-Year Outcomes of Mitral Valve-in-Valve Using the SAPIEN 3 Transcatheter Heart Valve.

Reference: Brian Whisenan et al. JAMA Cardiol. 2020;5(11):1245-1252. doi:10.1001/jamacardio.2020.2974.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....